ArticleCancer chemotherapy and pharmacology2021

Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.

Hiroaki Ikesue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.